Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 17:25:32 01/06/2026 BST			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.83K 82.01K 75.78K 144K 9.7M 147K 986K 383K 4.75M 380K 372K 16.47M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.94M 9.18M 8.48M 16.07M 1.09B 16.4M 110M 42.87M 531M 42.56M 41.63M 1.84B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
29/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
17/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/10/24	Top Midday Decliners	MT
14/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/09/24	Top Midday Decliners	MT
24/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Share Price

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	31/12/2018
Michael Golembiewski DFI	Director of Finance/CFO	54	31/08/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/02/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
11/01/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
11/01/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-	-100.00%	136
ARGENX SE	-1.53%	-1.43%	+71.67%	+129.70%	57.72B
WUXI APPTEC CO., LTD.	-2.45%	-7.32%	+65.23%	+83.15%	52.65B
INSMED INCORPORATED	+3.27%	+8.91%	+21.21%	+471.23%	24.46B
BIONTECH SE	-0.81%	+0.52%	-15.01%	-12.47%	23.84B
WUXI BIOLOGICS (CAYMAN) INC.	-3.05%	+3.06%	+42.36%	-5.66%	19.28B
GENMAB A/S	-0.24%	+5.11%	+38.76%	-25.95%	17.8B
PHARMAESSENTIA CORPORATION	+2.34%	+14.18%	+220.96%	+380.99%	17.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-6.73%	+9.90%	+36.04%	-	15.28B
EXELIXIS, INC.	-1.70%	+3.98%	+28.96%	+194.23%	14.35B
Average	+988.91%	+4.68%	+56.69%	+123.91%	24.27B
Weighted average by Cap.	-1.26%	+2.71%	+57.79%	+140.26%

	2022	2023
Net sales	-	2.2 1.93 1.78 1.65 3.12 210.94 3.19 21.45 8.33 103.23 8.27 8.09 358.34
Net income	-73.53M -64.5M -59.54M -55.02M -104M -7.04B -106M -716M -278M -3.45B -276M -270M -11.96B	-37.88M -33.23M -30.68M -28.35M -53.73M -3.63B -54.8M -369M -143M -1.78B -142M -139M -6.16B
Net Debt	4.59M 4.03M 3.72M 3.43M 6.51M 439M 6.64M 44.67M 17.36M 215M 17.23M 16.86M 746M	11.23M 9.85M 9.1M 8.4M 15.93M 1.08B 16.25M 109M 42.48M 526M 42.18M 41.26M 1.83B